| Kelli L Gramlich, | |
|
1925 Pacific Ave, Atlantic City, NJ 08401-6713 | |
| (609) 441-8023 | |
| Not Available |
| Full Name | Kelli L Gramlich |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 1925 Pacific Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134768419 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LC0200X | Nurse Practitioner - Critical Care Medicine | 26NJ00995700 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlanticare Regional Medical Center | Atlantic city, NJ | Hospital |
| Cape Regional Medical Center Inc | Cape may court house, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlanticare Physician Group Pa | 8527953660 | 495 |
News Archive
While the American Stroke Association reports that stroke is the third leading cause of death and one of the top causes of disability in the United States, young adults showing signs of suffering a stroke are sometimes misdiagnosed in hospital emergency rooms, preventing them from receiving early effective treatment that can prevent serious damage.
Providing notices that explain how physicians are paid appears to increase patients' knowledge about compensation models, does not harm trust and may increase the loyalty patients feel toward their physicians, according to a study in the Archives of Internal Medicine.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 3 days ago
| Entity Name | Atlanticare Physician Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093829608 PECOS PAC ID: 8527953660 Enrollment ID: O20040218000405 |
News Archive
While the American Stroke Association reports that stroke is the third leading cause of death and one of the top causes of disability in the United States, young adults showing signs of suffering a stroke are sometimes misdiagnosed in hospital emergency rooms, preventing them from receiving early effective treatment that can prevent serious damage.
Providing notices that explain how physicians are paid appears to increase patients' knowledge about compensation models, does not harm trust and may increase the loyalty patients feel toward their physicians, according to a study in the Archives of Internal Medicine.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 3 days ago
| Entity Name | Atlanticare Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568663250 PECOS PAC ID: 0648181578 Enrollment ID: O20040622000289 |
News Archive
While the American Stroke Association reports that stroke is the third leading cause of death and one of the top causes of disability in the United States, young adults showing signs of suffering a stroke are sometimes misdiagnosed in hospital emergency rooms, preventing them from receiving early effective treatment that can prevent serious damage.
Providing notices that explain how physicians are paid appears to increase patients' knowledge about compensation models, does not harm trust and may increase the loyalty patients feel toward their physicians, according to a study in the Archives of Internal Medicine.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelli L Gramlich, 1925 Pacific Ave, Atlantic City, NJ 08401-6713 Ph: (609) 441-8023 | Kelli L Gramlich, 1925 Pacific Ave, Atlantic City, NJ 08401-6713 Ph: (609) 441-8023 |
News Archive
While the American Stroke Association reports that stroke is the third leading cause of death and one of the top causes of disability in the United States, young adults showing signs of suffering a stroke are sometimes misdiagnosed in hospital emergency rooms, preventing them from receiving early effective treatment that can prevent serious damage.
Providing notices that explain how physicians are paid appears to increase patients' knowledge about compensation models, does not harm trust and may increase the loyalty patients feel toward their physicians, according to a study in the Archives of Internal Medicine.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
T2 Biosystems, Inc., a company developing the first decentralized clinical diagnostic solution that eliminates extensive sample preparation and enables rapid molecular and immunodiagnostic testing on a single instrument, today announced that it has raised approximately $15 million in a Series C financing. Proceeds from the financing will be used to accelerate the development and commercialization of T2 Biosystems' next generation diagnostic platform for use in the decentralized setting.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
› Verified 3 days ago
Mr. Matthew R Soos, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-572-8600 | |
Helene E Fedele, ACNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2922 Atlantic Ave, 2nd Floor, Atlantic City, NJ 08401 Phone: 609-437-2020 Fax: 609-345-4290 | |
Nediya Griffith, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2009 Bacharach Blvd, Atlantic City, NJ 08401 Phone: 609-344-5714 Fax: 609-575-6033 | |
Marisa B Scibilia, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave., Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Debra Walters-olaru, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 Boardwalk, Showboat Wellness Center, Atlantic City, NJ 08401 Phone: 609-343-4003 | |
Elaina M Nixon, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8146 |